VBIV VBI Vaccines: ערך חשבונאי למניה

Operational failure risks are minimized by distributing clinical trials across different CROs. The estimated book value per share confirms this stability, where the -0.22 level represents the current value. VBI Vaccines Inc. (VBIV) solidifies its status as a technological leader with a powerful R&D center and the eVLP platform. The use of virus structure mimicry enhances the immune response, which has facilitated the creation of advanced drugs against hepatitis B.

For the biopharmaceutical sector and the innovative VLP platform of VBI Vaccines Inc. (VBIV), the change in book value per share serves as an indicator of the capitalization of intellectual and tangible assets. This metric is calculated as the difference between total assets and liabilities divided by the number of shares, reflecting the actual value of assets per share and helping investors assess the intrinsic value of the business net of debt.